INDIANAPOLIS--Eli Lilly and Company has received FDA approval
to provide gemcitabine (Gemzar) to advanced pancreatic cancer
patients through a Treatment Investigational New Drug program.
The agent will be provided free of charge to patients who are
not candidates for surgery and who meet certain medical eligibility
criteria. Patients may have been previously untreated or have
had one prior chemotherapy regimen. Physicians may call 1-800-621-7111
for more information about the Treatment IND.